Amyotrophic Lateral Sclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
More importantly, our data imply different pathological processes underlying inclusion formation and cell death between both conditions; the pathogenesis in amyotrophic lateral sclerosis with FUS mutations appears to be more restricted to dysfunction of fused in sarcoma, while a more global and complex dysregulation of all FET proteins is involved in the subtypes of frontotemporal lobar degeneration with fused in sarcoma pathology.
|
21856723 |
2011 |
Amyotrophic Lateral Sclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we assessed vascular integrity <i>in vivo</i> throughout different disease stages, and investigated whether ANG treatment reverses vascular regression and prolongs motor neuron survival in the FUS (1-359) mouse model of ALS.
|
31383794 |
2019 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that decreased expression of Drosophila Caz is sufficient to cause degeneration of motoneurons and locomotive disability in the absence of abnormal cytoplasmic Caz aggregates, suggesting that the pathogenic mechanism underlying FUS-related ALS should be ascribed more to the loss of physiological FUS functions in the nucleus than to the toxicity of cytoplasmic FUS aggregates.
|
22724023 |
2012 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data indicate that a selective vulnerability of motor neurons expressing the pathogenic ALS-causing genes TDP-43 and FUS, is, at least in part, mediated through non-cell-autonomous mechanisms.
|
26174443 |
2015 |
Amyotrophic Lateral Sclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in genes coding for proteins involved in DNA damage response (DDR) and repair, such as C9orf72 and FUS (Fused in Sarcoma), are associated with neurodegenerative diseases and lead to amyotrophic lateral sclerosis (ALS).
|
29929116 |
2018 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutations in the gene coding for fused in sarcoma/translocated in liposarcoma (FUS) are responsible for some cases of both familial and sporadic forms of ALS.
|
23620769 |
2013 |
Amyotrophic Lateral Sclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus far most FUS mutations are missenses, and our findings, combined with those of others, confirm the importance of the C-terminal portion of the protein, adding additional support for FUS mutations having a critical role in ALS.
|
21160488 |
2011 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Landmark discoveries of mutations in the transactive response DNA-binding protein (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS) as causative of ALS and FTLD, combined with the abnormal aggregation of these proteins, have initiated a shifting paradigm for the underlying pathogenesis of multiple neurodegenerative diseases.
|
20400460 |
2010 |
Amyotrophic Lateral Sclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the presence and frequency of C-terminal FUS/TLS mutations in a German amyotrophic lateral sclerosis (ALS) cohort, including 133 patients with sporadic ALS (SALS) and 58 patients with FALS by sequence analysis of exons 13-15.
|
20660363 |
2010 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
This review summarizes recent studies on FUS self-assembling, including both aggregation and LLPS as well as their relationship with the pathology of ALS, FTLD, and other neurodegenerative diseases.
|
31022909 |
2019 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here we investigated the role of HuR in regulating two RBPs, TDP-43 and FUS/TLS, that have been linked genetically to amyotrophic lateral sclerosis.
|
25239623 |
2014 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings suggest that FUS is the pathological protein in a significant subgroup of sporadic FTD and reinforce the concept that FTD and amyotrophic lateral sclerosis are closely related conditions.
|
19674978 |
2009 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutations in the RNA- and DNA-binding proteins, fused in sarcoma (FUS) and transactive response DNA-binding protein 43 kDa (TDP-43), are responsible for 5-10% of familial and 1% of sporadic ALS cases.
|
25792726 |
2015 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
We expressed human FUS in rats to determine if FUS would induce ALS relevant respiratory changes to serve as an early stage disease indicator.
|
27793099 |
2016 |
Amyotrophic Lateral Sclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
It is known that mutations in the FUS nuclear localization signal (NLS) retain the protein to the cytosol, promote aggregate formation and are associated with amyotrophic lateral sclerosis.
|
30354839 |
2018 |
Amyotrophic Lateral Sclerosis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We find that rabies virus (RABV) spreads ALS phenotypes, including the formation of stress granules (SGs) with aberrant composition due to increased levels of FUS protein, as well as neurodegeneration and reduced restriction activity by FUS mutations.
|
31695598 |
2019 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
FUS (fused in sarcoma) proteinopathy is a group of neurodegenerative diseases characterized by the formation of inclusion bodies containing the FUS protein, including frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
|
30249657 |
2018 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
The full definition of the physiological RNA targets regulated by TDP-43 and FUS RNA-binding proteins (RBPs) represents an important issue in understanding the pathogenic mechanisms associated to these two proteins in amyotrophic lateral sclerosis and frontotemporal dementia.
|
26514432 |
2015 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
A prominent feature of both ALS and PD is the accumulation of protein inclusions in the cytoplasm of degenerating neurons; however, the particular proteins constituting these inclusions vary: the RNA-binding proteins TDP-43 and FUS are most notable in ALS, while α-synuclein aggregates into Lewy bodies in PD.
|
29243911 |
2018 |
Amyotrophic Lateral Sclerosis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of human ALS-causing FUS/TLS mutations in Drosophila caused an accumulation of ubiquitinated proteins, neurodegeneration, larval-crawling defect and early lethality.
|
21487023 |
2011 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
These FUS protein aggregates are known as pathological hallmarks in a subset of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) cases.
|
30002616 |
2018 |
Amyotrophic Lateral Sclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
FUS mutations were evident in 3.2% (4/124) of familial ALS, representing the second most common gene abnormality to be described in familial ALS after SOD1.
|
19965854 |
2010 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
The DNA/RNA binding proteins TAR DNA-binding protein 43 (TDP-43) and fused-in-sarcoma (FUS) are genetically linked to amyotrophic lateral sclerosis and frontotemporal lobar dementia, while the inappropriate cytoplasmic accumulations of TDP-43 and FUS are observed in a growing number of late-onset pathologies including spinocerebellar ataxia 3, Alzheimer's and Huntington's diseases (HD).
|
23172908 |
2013 |
Amyotrophic Lateral Sclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Overexpression and mislocalization of wild-type FUS likely contribute to ALS pathogenesis in these cases.
|
23847048 |
2013 |
Amyotrophic Lateral Sclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TDP-43 and FUS/TLS have striking structural and functional similarities, implicating alterations in RNA processing as a key event in ALS pathogenesis.
|
19303844 |
2009 |